When do the patents on IRON DEXTRAN expire, and when will generic IRON DEXTRAN be available?

Sponsor	Phase
Assiut University	PHASE4
NanoEcho AB	PHASE2
Hamad Medical Corporation	NA

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	IRON DEXTRAN	iron dextran	INJECTABLE;INJECTION	010787-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: October 15, 2026

Iron dextran is a mature parenteral iron product with low patent risk, limited brand differentiation, and declining strategic importance relative to newer intravenous iron therapies. Its commercial value comes from low acquisition cost and use in patients who need rapid iron replacement, but demand is constrained by safety concerns, administration requirements, and competition from ferric carboxymaltose, ferric derisomaltose, ferumoxytol, and iron sucrose.

The market is fragmented across branded, generic, hospital, and specialty-pharmacy channels. Public company filings generally do not disclose iron dextran revenue separately. The product class remains commercially viable, but its financial trajectory is best characterized as mature and price-sensitive rather than growth-oriented.

What is iron dextran and how is it used?

Iron dextran is an injectable iron-carbohydrate complex used to treat iron-deficiency anemia when oral iron is ineffective, poorly tolerated, or clinically inappropriate. It is administered intravenously or intramuscularly, depending on the product labeling and clinical setting.

The principal U.S. branded product is INFeD, an iron dextran injection historically associated with low-molecular-weight iron dextran. Iron dextran products are used in hospitals, dialysis centers, oncology practices, hematology clinics, and selected outpatient infusion settings.

What clinical advantages does iron dextran have?

Iron dextran can deliver a large replacement dose in relatively few administrations. That characteristic can reduce infusion visits compared with iron sucrose, which commonly requires multiple smaller doses. The benefit is most relevant where clinicians prioritize total-dose replacement and where the institution has protocols for monitoring hypersensitivity reactions.

Its disadvantages include:

Risk of serious hypersensitivity reactions, including anaphylaxis.
Need for trained administration and post-infusion observation.
Historical concern regarding high-molecular-weight formulations.
Greater competition from newer products with simpler dosing or more favorable tolerability perceptions.
Less commercial promotion than newer intravenous iron brands.

The FDA label for INFeD includes a boxed warning for serious hypersensitivity reactions and requires that resuscitation equipment and personnel trained to manage anaphylaxis be immediately available.[1]

What is the FDA regulatory status of iron dextran?

INFeD is an FDA-approved prescription injection marketed under New Drug Application 017441. The product is an iron dextran complex indicated for patients with documented iron deficiency who cannot be adequately treated with oral iron.[1][2]

Iron dextran is a small-molecule or non-biologic drug product, not a biologic. It is therefore not subject to the FDA biosimilar pathway. Competitive products are generally approved through abbreviated or full New Drug Applications, depending on the product and regulatory history.

Does iron dextran have FDA exclusivity?

Iron dextran has no meaningful remaining new-drug exclusivity based on the age of the product. INFeD was approved decades ago, and any original statutory exclusivity has expired.

The main commercial barriers are regulatory compliance, manufacturing validation, product quality, supply reliability, and hospital formulary access. These barriers are materially weaker than active patent protection.

What is the Orange Book status of INFeD?

INFeD is listed in FDA drug databases as an approved iron dextran injection product. For a mature product of this age, Orange Book value depends less on patent protection and more on whether any currently listed patents remain active and relevant to the marketed presentation.

No widely recognized, commercially blocking patent estate is associated with the core iron dextran active ingredient. The principal composition and use concepts are long past ordinary patent life. Current competitive analysis should focus on the specific National Drug Code, manufacturer, dosage form, and Orange Book entry because product-level listings can change through transfers, discontinuations, or updates.[2]

What patents protect iron dextran?

The core iron dextran technology is effectively off-patent. Historical patents covering iron-carbohydrate complexes, preparation methods, and injectable compositions have expired or lost practical blocking value.

Are there active formulation patents for iron dextran?

No major active formulation patent is broadly recognized as protecting the core commercial use of iron dextran in the United States. Potentially relevant rights could still arise around:

Manufacturing controls for particle-size distribution.
Stability improvements.
Container-closure systems.
Preservative systems.
Concentration or dosing presentations.
Process controls for dextran molecular-weight distribution.

These rights would generally be narrower than a composition patent and would not necessarily prevent a competing manufacturer from producing iron dextran through a different process.

Are there method-of-use patents for iron dextran?

The principal uses of iron dextran, including treatment of iron-deficiency anemia and replenishment of iron stores, are established medical uses. Broad method-of-use patents for those indications are unlikely to create meaningful exclusivity.

A narrow patent could theoretically cover a particular patient population, dosing regimen, infusion protocol, or combination therapy. Such rights would have limited commercial impact unless they were listed for the reference product and enforceable against a generic applicant.

When does iron dextran lose exclusivity?

Iron dextran lost composition and original regulatory exclusivity many years ago. There is no single upcoming loss-of-exclusivity date comparable to a modern branded medicine because the product is already mature and generic competition exists.

Exclusivity category	Current position
Core composition patent	Expired or commercially irrelevant
Original FDA exclusivity	Expired
Broad method-of-use protection	Not commercially significant
Formulation protection	No widely recognized blocking estate
Biosimilar exclusivity	Not applicable
Generic competition	Established or potentially available by product and market
Main remaining barriers	Manufacturing, quality, supply, contracting, and safety controls

How many patents cover iron dextran?

The number of historical patent documents relating to iron dextran may be substantial, but the number of enforceable patents that materially block current U.S. competition is effectively zero based on the mature status of the technology.

A patent count that includes expired process patents would overstate commercial protection. The relevant question is whether a patent remains unexpired, covers the marketed product, is enforceable in the relevant jurisdiction, and is listed or otherwise actionable against a competing manufacturer.

Which companies manufacture or compete with iron dextran?

The competitive landscape includes the originator or legacy brand supplier, generic injectable manufacturers, contract manufacturers, and companies selling alternative intravenous iron products.

Direct iron dextran competitors

Direct competition comes from suppliers of iron dextran injection, including products marketed under the INFeD name and generic or institutional channels. Availability can vary by country, manufacturer, and supply conditions.

Therapeutic competitors

The more important competition comes from other intravenous iron products:

Product	Active ingredient	Typical commercial positioning
INFeD	Iron dextran	Low-cost, high-dose iron replacement
Venofer	Iron sucrose	Established dialysis and hospital use
Ferrlecit	Sodium ferric gluconate complex	Dialysis and outpatient infusion
Feraheme	Ferumoxytol	High-dose dosing with branded positioning
Injectafer	Ferric carboxymaltose	Large-dose administration and broad specialty use
Monoferric	Ferric derisomaltose	Large-dose administration and outpatient use

Venofer and Ferrlecit have long-standing positions in dialysis care. Injectafer, Feraheme, and Monoferric compete through dosing convenience, physician familiarity, contracting, and marketing rather than through direct patent protection over iron dextran.

How does iron dextran compare with newer intravenous iron products?

Iron dextran has a lower-cost profile but a more challenging safety and administration profile. Newer products generally command higher prices because they offer branded support, large-dose protocols, differentiated labels, or stronger commercial infrastructure.

Factor	Iron dextran	Newer IV iron products
Patent protection	Minimal or expired	Product-specific patents may remain
Acquisition cost	Generally low	Often substantially higher
Dose administration	Can support large replacement doses	Often designed for one or two administrations
Hypersensitivity concern	Material clinical consideration	Still present, but product positioning may differ
Physician promotion	Limited	More active for branded products
Hospital purchasing	Price-driven	Contracting and clinical protocols
Revenue growth potential	Low	Higher for differentiated brands
Biosimilar exposure	Not applicable	Not applicable to most small-molecule IV irons

Iron dextran can remain attractive where a health system has established protocols and seeks to minimize drug acquisition cost. Newer agents may be favored where infusion-center efficiency, product familiarity, or commercial contracting offsets the higher price.

What is the market size and financial trajectory for iron dextran?

Publicly available financial data do not provide a reliable, consolidated global revenue figure for iron dextran. Manufacturers generally report iron dextran within broader hospital pharmaceutical, generic injectable, or specialty-product categories.

The financial trajectory has four main characteristics:

Revenue is mature rather than expansionary.
Unit demand is relatively stable but varies with anemia prevalence, dialysis activity, surgery, oncology treatment, and intravenous treatment practices.
Price realization is pressured by generic competition and hospital procurement.
Gross margins depend heavily on manufacturing cost, supply continuity, and contract access.

What drives iron dextran demand?

Demand is supported by:

Chronic kidney disease and dialysis.
Heavy menstrual bleeding.
Gastrointestinal blood loss.
Malabsorption and inflammatory disease.
Cancer-associated anemia.
Preoperative anemia management.
Patients unable to tolerate oral iron.
Health-system efforts to reduce repeated infusion visits.

The strongest volume opportunities are in cost-sensitive institutional channels. Commercial growth is limited because iron dextran does not have a strong premium-pricing story.

What pressures iron dextran revenue?

Revenue faces structural pressure from:

Lower-cost generic injectable products.
Substitution with iron sucrose or ferric gluconate.
Adoption of high-dose branded products.
Hospital preference for standardized protocols.
Safety-related prescribing caution.
Product shortages or discontinuations.
Limited manufacturer investment in education and promotion.

The product can maintain volume while losing revenue through price compression. That pattern is common in mature injectable generics.

What generic entry risks exist for iron dextran?

Generic entry risk is already realized rather than prospective. The principal risk to a branded iron dextran supplier is continued substitution by lower-priced suppliers, not a future patent cliff.

What is the Paragraph IV risk?

Paragraph IV litigation is unlikely to be a central issue for the core iron dextran market because the foundational product technology is old and broad patent protection has expired. A new abbreviated application could still challenge any late-listed patent covering a specific formulation, labeling element, or delivery configuration, but such a challenge would be product-specific.

The commercial importance of Paragraph IV activity is therefore low compared with newer branded products. Any filing must be evaluated against the current Orange Book listing for the relevant reference product.

What patent litigation affects iron dextran?

No major, widely recognized patent litigation campaign currently defines the U.S. iron dextran market. Litigation exposure is more likely to involve:

Product liability claims concerning hypersensitivity reactions.
Manufacturing and quality disputes.
Contract or supply disagreements.
Regulatory enforcement concerning sterile injectable production.
Patent disputes over a narrow formulation or process, if one is asserted.

This distinction matters. Iron dextran’s principal legal risk is operational and product-liability exposure, not exclusionary patent litigation.

What manufacturing and intellectual-property barriers exist?

Manufacturing is a more important barrier than patents. Iron dextran is a complex iron-carbohydrate injectable product. Consistency in molecular-weight distribution, iron content, sterility, endotoxin control, stability, and container compatibility is necessary for regulatory compliance.

Which manufacturing controls matter most?

Critical controls include:

Reproducible dextran complex formation.
Iron-to-carbohydrate ratio.
Particle and molecular-weight distribution.
Sterility assurance.
Endotoxin limits.
Stability during storage.
Extractables and leachables from packaging.
Validated fill-finish operations.
Consistent release testing.

These requirements can limit the number of dependable suppliers even when patent protection is absent. Injectable manufacturing capacity is difficult to replace quickly, and quality failures can create disproportionate commercial disruption.

What licensing deals affect iron dextran?

No major recent licensing transaction is widely associated with the core iron dextran market. The product is more likely to move through asset transfers, manufacturing agreements, distributor arrangements, or generic portfolio acquisitions than through high-value discovery licensing.

Relevant commercial arrangements may include:

Contract manufacturing of sterile injectable product.
Regional distribution rights.
Transfer of an approved application.
Acquisition of a generic injectable portfolio.
Hospital group-purchasing contracts.
Specialty-pharmacy distribution agreements.

These arrangements can affect market share without changing the underlying patent position.

What generic launch scenarios are most likely?

The most likely market scenarios are:

Continued low-price institutional supply

Iron dextran remains available through hospitals and infusion providers that prioritize acquisition cost and have established reaction-management protocols. This is the base case.

Manufacturer exit or intermittent shortage

Because margins are limited, a supplier may discontinue or reduce production after quality events, capacity constraints, or unfavorable contracting. A small number of suppliers can make the market vulnerable to temporary shortages.

Selective substitution by newer products

Clinicians may shift patients to ferric carboxymaltose, ferric derisomaltose, ferumoxytol, or iron sucrose when dosing convenience, formulary policy, or safety preferences justify higher cost.

Price compression without volume collapse

Iron dextran volume can remain stable while net pricing declines. This is the most likely long-term financial pattern.

How strong is the iron dextran patent estate?

The patent estate is weak as a source of exclusivity but durable as a technical manufacturing base. The product’s commercial defensibility rests on regulatory history, manufacturing execution, hospital contracts, and supply reliability.

Estate component	Strength
Core composition	Very weak
Broad therapeutic use	Very weak
Modern formulation claims	Limited and product-specific
Manufacturing know-how	Moderate
Regulatory history	Moderate
Brand recognition	Low to moderate
Hospital contracting	Potentially material
Supply reliability	Potentially decisive

What is the outlook for iron dextran through the medium term?

Iron dextran is likely to remain a low-growth, price-sensitive intravenous iron product. Its demand base is supported by chronic anemia and continued use of parenteral iron, but its ability to expand revenue is limited.

The strongest commercial positions will belong to suppliers that control dependable sterile manufacturing, maintain regulatory compliance, secure hospital contracts, and manage product liability risk. Patent-based value creation is unlikely. A buyer or licensee should value the product primarily on recurring institutional volume, manufacturing economics, supply resilience, and portfolio fit.

Key Takeaways

Iron dextran is a mature injectable iron product with expired core exclusivity.
INFeD is the principal U.S. branded reference product, while generic and institutional competition constrains pricing.
The product is not a biologic and has no biosimilar pathway.
No major active patent estate is widely recognized as blocking current competition.
Paragraph IV risk and patent litigation are limited relative to newer branded medicines.
Manufacturing quality, sterile capacity, and supply continuity are more important than patents.
Newer products compete through dosing convenience, contracting, and commercial support.
Public companies generally do not disclose iron dextran revenue separately.
The financial trajectory is stable-to-declining in price, with limited unit growth.
The main investment case is operational efficiency and dependable supply, not patent-driven upside.

FAQs

Is iron dextran still commercially relevant?

Yes. It remains relevant in cost-sensitive hospitals and infusion settings, particularly where clinicians use high-dose replacement protocols and have established hypersensitivity-monitoring procedures.

Is INFeD protected by patents?

The core iron dextran technology is not protected by a commercially meaningful modern patent estate. Any current patent analysis must review the specific product listing and jurisdiction.

Is iron dextran cheaper than Injectafer?

Iron dextran is generally positioned as a lower-cost alternative, but actual net cost depends on dose, administration fees, hospital contracts, wastage, and reimbursement.

Can a generic manufacturer launch iron dextran without a patent license?

A manufacturer may be able to enter without a license to expired core patents, subject to FDA approval, applicable listed patents, manufacturing compliance, labeling requirements, and other regulatory obligations.

What is the main risk to an iron dextran investment?

The main risks are price compression, limited market growth, sterile injectable manufacturing failures, product shortages, hypersensitivity-related liability, and substitution by newer intravenous iron products.

References

U.S. Food and Drug Administration. (2023). INFeD (iron dextran injection) prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
DailyMed. (2024). INFeD: Iron dextran injection label. National Library of Medicine. https://dailymed.nlm.nih.gov/
U.S. Food and Drug Administration. (2013). Guidance for industry: Drug products or biological products that contain nanomaterials. FDA.
Auerbach, M., & Macdougall, I. C. (2014). Safety of intravenous iron formulations: Facts and folklore. Blood Transfusion, 12(3), 296-300. https://doi.org/10.2450/2014.0062-13

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	27
Clinical Trials:	75
What excipients (inactive ingredients) are in IRON DEXTRAN?	IRON DEXTRAN excipients list
DailyMed Link:	IRON DEXTRAN at DailyMed

AI Deep Research

Questions you can ask:

Summary for IRON DEXTRAN

Recent Clinical Trials for IRON DEXTRAN

Anatomical Therapeutic Chemical (ATC) Classes for IRON DEXTRAN